Aims To investigate the effect of the antiretroviral protease inhibitors saquinavir (soft gelatin capsule) and ritonavir on the pharmacokinetic properties and tolerability of sildena®l and to investigate the effect of sildena®l on the steady-state pharmacokinetics of saquinavir and ritonavir. Methods Two independent, 8 day, open, randomized, placebo-controlled, parallelgroup studies (containing a double-blind crossover phase) were conducted at P®zer Clinical research units (Canterbury, UK. and Brussels, Belgium). Twenty-eight healthy male volunteers entered each study. In each study, volunteers were randomized (n=14 per group) to receive sildena®l on day 1 followed by a 7-day treatment period (days 2±8) with saquinavir or placebo (Study I) or ritonavir or placebo (Study II). Sildena®l or placebo (Study I and Study II) was administered alternately on day 7 or day 8, depending on initial randomization. The effect of saquinavir and ritonavir on the pharmacokinetics of sildena®l and its primary circulating metabolite (UK-103, 320) and the effect of single-dose sildena®l on the steady-state pharmacokinetics of saquinavir (1200 mg three times daily) and ritonavir (500 mg twice daily) were determined. The safety and tolerability of sildena®l coadministered with saquinavir or ritonavir were also assessed. Results Both protease inhibitors signi®cantly increased C max , AUC, t max and t K values for both sildena®l and UK-103, 320. Ritonavir showed a signi®cantly greater effect than saquinavir with increases in sildena®l AUC and C max of 11-fold (95% CI: 9.0, 12.0) and 3.9-fold (95% CI: 3.2, 4.9), respectively. This compared with increases of 3.1-fold (95% CI: 2.5, 4.0) and 2.4-fold (95% CI: 1.8, 3.3) for coadministration with saquinavir. In contrast, the steady-state pharmacokinetics of saquinavir and ritonavir were unaffected by sildena®l. The increases in systemic exposure to sildena®l and UK-103, 320 were not associated with an increased incidence of adverse events or clinically signi®cant changes in blood pressure, heart rate or ECG parameters. Conclusions These results indicate that both saquinavir and ritonavir modify the pharmacokinetics of sildena®l presumably through inhibition of CYP3A4. The more pronounced effect of ritonavir may be attributed to its additional potent inhibition of CYP2C9. No change in safety or tolerability was observed when sildena®l was coadministered with either protease inhibitor. However, given the extent of the interactions, a lower sildena®l starting dose (25 mg) should be considered for patients receiving saquinavir and it is recommended not to exceed a maximum single dose of 25 mg in a 48 h period for patients receiving ritonavir.
Introduction
Sildena®l (Viagra 1 , P®zer) is an orally active phosphodiesterase-type-5 inhibitor that is effective in the treatment of male erectile dysfunction of organic, psychogenic or mixed aetiology [1] . Given the demonstrated ef®cacy, ease of use, good tolerability and positive impact on patients' quality of life with sildena®l, it has assumed a major role in the treatment of erectile dysfunction [2] . The drug is eliminated predominantly by hepatic metabolism, being subjected to extensive ®rst pass N-demethylation via the cytochrome P450 isoenzymes CYP3A4 (major route) and CYP2C9 (minor route) [2, 3] . Thus, there is scope for pharmacokinetic interaction between sildena®l and coadministered drugs that act as substrates, inhibitors or inducers of these isoenzymes. Increased systemic exposure to sildena®l has been described following its coadministration with the established CYP3A4 inhibitor erythromycin [4] .
Sexual (including erectile) dysfunction is a relatively common complaint in men with HIV infection [5±7], a population that routinely receives multiple medication most notably, antiretroviral drug combinations. The effectiveness of protease inhibitors in reducing the morbidity and mortality associated with advanced HIV infection is well established [8, 9] . However, these agents have been reported to interact with several other drugs, including azole antifungals, clarithromycin, rifamycins and non-nucleoside reverse transcriptase inhibitors [10, 11] . The protease inhibitors saquinavir, ritonavir, indinavir, nel®navir and amprenavir are metabolized by and inhibit the CYP3A4 isoenzyme [12±18] . In addition, at therapeutic concentrations, ritonavir inhibits a number of other cytochrome P450 isoenzymes, including CYP2C9, CYP2C19 and CYP2D6 [19±21] .
As effective antiretroviral therapy continues to improve physical wellbeing an increased awareness of erectile dysfunction is likely to emerge. Patients have voiced a need for advice on erectile dysfunction and concerns surrounding potential interactions between sildena®l and protease inhibitors have been raised [22] . Merry et al. investigated the interaction of sildena®l and indinavir in HIV-positive patients [23] . This study showed that coadministration of sildena®l 25 mg did not signi®cantly alter plasma indinavir concentrations. However, plasma sildena®l AUC was markedly increased in the presence of indinavir compared with historical controls. This suggests that a lower starting dosage of sildena®l may be appropriate in this clinical setting.
Given the potential for indinavir to alter the kinetics of sildena®l, this study was undertaken to investigate the pharmacokinetic interaction between sildena®l and the protease inhibitors saquinavir and ritonavir in healthy male volunteers.
Methods

Subjects and study design
Two groups of 28 healthy male volunteers (18±45 years) weighing between 60 and 100 kg and with a body mass index within the permitted range (Quetelet's index range 18±28) were enrolled in two separate, randomised, openlabel, placebo-controlled, parallel-group studies, each containing a double-blind crossover phase. Volunteers were excluded if they showed signs of clinical disease, orthostatic hypotension, drug abuse or excessive alcohol consumption (>21 units/week). Those with a history of allergy, abnormal laboratory results or recent use of a prescription drug (within 3 weeks) or investigational drug (within 4 months) were also excluded. Written informed consent was obtained from each subject prior to study entry and the study protocols were reviewed and approved by the relevant local ethics committees.
In each study, volunteers were randomised to receive oral sildena®l 100 mg on day 1 followed by oral saquinavir (soft gelatin capsule) or placebo (Study I) or oral ritonavir or placebo (Study II) for the next 7 days (days 2±8). In both studies sildena®l (100 mg) and placebo were administered alternately on days 7 and 8. This design allowed assessment of both the effect of saquinavir and ritonavir on the pharmacokinetics of single-dose sildena®l, and the effect of single dose sildena®l on the steady-state pharmacokinetics of saquinavir and ritonavir. Saquinavir (soft gelatin capsule) 1200 mg three times daily was administered on days 2±8 and ritonavir 300, 400 and 500 mg twice daily was administered on days 2, 3, and 4±8, respectively. The study schedule and treatment regimens are presented in Table 1 .
Pharmacokinetic measurements
Blood samples (7 or 10 ml) for pharmacokinetic analyses were taken on days 1, 7, and 8 at time 0 (baseline premorning dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h after the morning dose. Sildena®l administered as a single 100 mg dose; saquinavir administered at a dosage of 1200 mg three times daily; ritonavir administered at a dosage of 300, 400 and 500 mg twice daily on days 2, 3 and 4±8, respectively. *: intergroup comparison (saquinavir/ritonavir vs placebo) of change in sildena®l pharmacokinetics from day 1 to day 7/8; {: geometric mean; {: arithmetic mean. Table 3 Effect of saquinavir and ritonavir on the pharmacokinetics of the sildena®l metabolite UK-103,320.
Treatment regimen
Pharmacokinetic parameter AUC{ (ng ml x1 h) Sildena®l administered as a single 100 mg dose; saquinavir administered at a dosage of 1200 mg three times daily; ritonavir administered at a dosage of 300, 400 and 500 mg twice daily on days 2, 3 and 4±8, respectively. a:AUC value from time zero to the ®nal quanti®able concentration (AUC t ). *: intergroup comparison (saquinavir/ritonavir vs placebo) of change in UK-103 320 pharmacokinetics from day 1 to day 7/8; {: geometric mean; {: arithmetic mean. The simultaneous determination of sildena®l (Viagra) and its metabolite (UK-103 320) were analysed using automated sequential trace enrichment of dialysates and high-performance liquid chromatography [24] . The limits of quanti®cation were 1 ng ml x1 for both sildena®l and UK-103 320. The overall imprecision (CV) was 5.1, 3.2 and 3.0% for sildena®l and 3.4, 3.1 and 2.9% for UK-103 320 concentrations of 3.00, 125 and 200 ng ml x1 , respectively. The inaccuracy (bias) of the assay at all concentrations ranged from x2.3% to 3.5% for sildena®l and x7.0% to 4.8% for UK-103 320.
The analytical procedure for analysing saquinavir and ritonavir in plasma utilized a Sciex API 300 instrument with a heated nebuliser source. The analytes were isolated by solid phase extraction and the resultant sample extracts were injected onto the LC/MS/MS detection system. The limits of quanti®cation were 1 ng ml x1 and 10 ng ml for the saquinavir and ritonavir assays, respectively. The overall imprecision of the saquinavir assay (CV) was 7.8, 6.6 and 6.3% at target concentrations of 3.00, 120 and 799 ng ml x1 , respectively. The inaccuracy (bias) of the assay at all concentrations ranged from x5.4% to 0.8%. The overall imprecision of the ritonavir assay (CV) was 7.0, 4.7 and 5.6% at target concentrations of 30.0, 1001 and 8010 ng ml x1 , respectively. The inaccuracy (bias) of the assay at all concentrations ranged from x10.0% to 7.3%.
All pharmacokinetic parameters were calculated by noncompartmental analysis using WinNonlin TM Version 1.1 (Pharsight Corporation). The pharmacokinetic parameters calculated for sildena®l and its primary metabolite, UK-103,320, were: maximum observed plasma concentration (C max ), time to reach maximum plasma concentration (t max ), apparent terminal elimination phase rate constant (l z ), area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC(0,t)) and area under the plasma concentration-time curve extrapolated to in®nity (AUC). On days 7 and 8, C max , t max and the area under the plasma concentrationtime curve over the dosing interval (AUCt) were calculated for saquinavir and ritonavir in the presence of sildena®l or placebo. Additional (premorning dose) blood samples were taken to determine trough plasma concentrations (C min ) of saquinavir and ritonavir.
Safety and tolerability
Laboratory safety tests, vital sign measurements and electrocardiograms (ECG) were performed at regular intervals during the study. The nature and severity of all adverse events were recorded throughout the study period. The investigators obtained all adverse events using non leading questions and recorded their opinion of the relationship to study treatment.
Statistical analysis
Sildena®l and UK-103 320 pharmacokinetic parameters An An analysis of variance (ANOVA) appropriate to the study design was conducted for sildena®l (natural-log transformed AUC and C max and untransformed l z and t max )
and UK-103 320 (natural-log transformed AUC(0,t) and C max and untransformed t max ). Differences between the mean pharmacokinetic values of sildena®l on day 1 and days 7/8 were calculated for each treatment group (i.e. saquinavir, ritonavir or placebo). The two active treatment groups (i.e. saquinavir and ritonavir) were compared with their corresponding placebo group by estimating the intergroup difference in change from day 1 to days 7/8, together with the corresponding standard error and 95% con®dence interval (95% CI). Saquinavir and ritonavir Cmin values were plotted to assess attainment of steady-state plasma levels. Steady-state saquinavir and ritonavir AUC(t) and C max values (both natural-log transformed) and t max (untransformed) were subjected to an ANOVA appropriate to the study design. Differences between mean pharmacokinetic values recorded in the presence of sildena®l or placebo were estimated, together with the associated standard errors and 95% CIs.
Results
Demographic characteristics
A total of 27 and 28 subjects completed Studies I and II, respectively, and were included in the pharmacokinetic analysis; one subject withdrew from Study I with a nontreatment-related adverse event. All enrolled subjects were evaluated for safety. Subjects included in the two studies were predominantly Caucasian (96.4%) and ranged in age from 18 to 44 (mean 28.8) years.
Effect of saquinavir on sildena®l and UK-103, 320 pharmacokinetics
Pharmacokinetic analysis was performed on data from 27 of the 28 subjects in the saquinavir study. The mean plasma concentration pro®les for sildena®l and UK-103, 320 on day 1, and in the presence of saquinavir or placebo on day 7/8, are shown in Figure 1a ,b. Mean pharmacokinetic parameters for sildena®l and UK-103, 320 are summarized in Tables 2 and 3, respectively. Multiple dosing with saquinavir produced signi®cant increases in sildena®l AUC and C max values (both P<0.0001) and signi®cantly delayed t max (P=0.0012) relative to placebo. There was a 3.1-fold (95% CI: 2.5, 4.0) increase in AUC and a 2.4-fold (95% CI: 1.8, 3.3) increase in C max , while t max was delayed by 2.6 h (95% CI: 1.1, 4.1 h). Multiple dosing with saquinavir also signi®cantly (P=0.012) decreased l z of sildena®l by 0.046/h (95% CI: x0.8, x0.1), resulting in an increase in the t K of sildena®l of approximately 1 h. However, by 24 h postdose, mean plasma sildena®l concentrations had declined to levels comparable to those recorded in the placebo group (Figure 1a) .
In the case of the metabolite UK-103,320, multiple dosing with saquinavir increased its AUC 2.3-fold (95% CI: 1.9, 2.9; P<0.0001) and delayed its t max by 3.9 h (95% CI: 1.5, 6.3 h; P=0.002) relative to placebo, but had no signi®cant effect on its C max or l z values. 
Effect of ritonavir on sildena®l and UK-103, 320 pharmacokinetics
Pharmacokinetic analysis was performed on data from all 28 subjects in the ritonavir study. The mean plasma concentration pro®les for sildena®l and UK-103, 320 on day 1, and in the presence of ritonavir or placebo on day 7/ 8, are shown in Figure 2a ,b. Mean pharmacokinetic parameters for sildena®l and UK-103,320 are summarized in Tables 2 and 3 , respectively. Multiple dosing with ritonavir produced signi®cant increases in sildena®l AUC and C max (both P<0.0001) and signi®cantly delayed t max (P=0.0018) relative to placebo. There was an 11-fold (95% CI: 9.0, 12.0) increase in AUC and a 3.9-fold (95% CI: 3.2, 4.9) increase in C max , while t max was delayed by 3.1 h (95% CI: 1.3, 4.9 h). In addition, multiple dosing with ritonavir signi®cantly (P=0.0003) decreased l z of sildena®l by 0.06 h x1 (95% CI: x0.09, x0.03), resulting in an increase in its t K of 1.8 h. Mean plasma sildena®l concentrations remained elevated throughout the dosing interval, with mean concentrations 24 h postdose similar to the maximum mean concentrations observed in the absence of ritonavir (placebo group) (Figure 2a) .
For the metabolite UK-103,320, multiple dosing with ritonavir signi®cantly increased its AUC(0,t) 1.7-fold (95% CI: 1.4, 2.2; P<0.0001), decreased its C max 0.5-fold (95% CI: 0.37, 0.71; P=0.0002) and delayed its t max by 9.7 h 
Study II
Adverse events
Total number of subjects with adverse events
Discontinued therapy due to adverse event 0 00 00 00 0 0 Headache  5  04  01  07  5  0  Asthenia  0  05  05  02  0  1  Vasodilation  6  06  01  03  4  1  Postural hypotension  0  03  00  00  2  0  Diarrhoea  0  03  02  00  0  0  Nausea  1  04  04  00  0  0  Dyspepsia  1  02  02  00  0  0  Paresthesia  0  04  05  00  0  0  Dizziness  0  3  01  00  1  0  Rhinitis  0  3  00  01  2  0  Abnormal vision  1  3  00  00  0  0 (95% CI: 5.8, 14 h; P=0.0001) relative to placebo. Due to the extent of the drug interaction, it was not possible to characterize the elimination phase, and thus the l z or t K values.
Effect of single dose sildena®l on the steady-state pharmacokinetics of saquinavir and ritonavir
Visual inspection of the predose (trough) plasma saquinavir and ritonavir concentrations during the course of the studies indicated that steady state was achieved by day 7 with both protease inhibitors. Mean steady-state pharmacokinetic values for saquinavir and ritonavir are summarized in Table 4 . Sildena®l had no signi®cant effect on steady-state AUC(t), C max or t max values of either saquinavir or ritonavir.
Safety and tolerability of sildena®l in combination with saquinavir or ritonavir
The most common adverse events reported with sildena®l were headache, facial¯ushing (vasodilatation), dizziness, abnormal vision and rhinitis. Coadministration of sildena®l with either saquinavir or ritonavir did not signi®cantly affect the incidence or severity of these adverse events ( Table 5 ). The increases in systemic bioavailability of sildena®l caused by these protease inhibitors, were not associated with clinically signi®cant laboratory abnormalities or changes in blood pressure, heart rate or ECG parameters.
Discussion
Sildena®l is subject to extensive oxidative metabolism in vitro, undergoing N-demethylation to UK-103,320, a reaction mediated by the low-af®nity, high-capacity CYP3A4 isoenzyme (major route) and the high-af®nity, low-capacity CYP2C9 isoenzyme (minor route) [2, 3] . Coadministration of sildena®l with inhibitors of these isoenzymes can therefore be expected to affect its pharmacokinetics. This is substantiated by the approximately 3-fold increase in peak plasma sildena®l concentrations obtained in the presence of the CYP3A4 inhibitor erythromycin [25] .
The protease inhibitors are subject to extensive ®rst-pass metabolism by the hepatic cytochrome P450 system, in particular by the CYP3A4 isoenzyme [13] , and in addition act as inhibitors of CYP3A4 [20, 22] . In vitro studies with human hepatic microsomes indicate that, of the currently available protease inhibitors, ritonavir is the most potent inhibitor of CYP3A4 and CYP2C9, while saquinavir is the least potent inhibitor of CYP3A4 with only weak in vitro inhibitory activity against CYP2C9 [20, 22, 26] .
Thus, IC 50 values for inhibition of CYP3A4-mediated testosterone 6b-hydroxylation by ritonavir and saquinavir were 0.034 and 2.14 mmol l x1 , respectively. Corresponding IC 50 values for inhibition of CYP2C9-mediated tolbutamide hydroxylation were 4.2 and 53.9 mmol l x1 , respectively [19] . However, it should be recognized that the estimated IC 50 for the effect of saquinavir on CYP2C9 is more than 10-fold higher than the mean maximum observed concentrations in patients treated with saquinavir soft gelatin formulation at a dose of 1200 mg three times daily [17] . Therefore, administration of saquinavir soft gelatin formulation is unlikely to result in signi®cant inhibition of CYP2C9 in vivo.
In this study, there were signi®cant increases in C max and AUC of sildena®l (2.4-and 3.1-fold, respectively) and signi®cant prolongation of its t max (by 2.6 h) during multiple dosing with saquinavir 1200 mg three times daily in human volunteers. This indicates that saquinavir inhibits the CYP3A4-mediated ®rst pass metabolism of sildena®l. The extent of the interaction with saquinavir appears comparable to that obtained with erythromycin (see above) and indinavir [23] . The modest increase in t K of sildena®l (by 1.0 h) indicates a limited effect of saquinavir on the systemic clearance of sildena®l. In addition, the signi®cant increase in AUC (2.3-fold) and prolongation of t max (by 3.9 h) of the sildena®l metabolite UK-103 320 suggests that saquinavir also inhibits the systemic metabolism of UK-103,320, a process also thought to be mediated by CYP3A4.
Ritonavir had a much greater effect than saquinavir on the pharmacokinetics of sildena®l. This provides further evidence for the involvement of the cytochrome P450 system in the sildena®l±protease inhibitor interaction. The 11-fold increase in sildena®l's AUC and high plasma concentrations, even at 24 h postdose, can be attributed to the potent inhibition by ritonavir of both the major (CYP3A4) and minor (CYP2C9) routes of sildena®l metabolism [20±22] . This effectively prevented the possibility of any compensatory shift in ®rst pass metabolism of sildena®l through the secondary CYP2C9-mediated pathway and, in addition, inhibited the systemic clearance of sildena®l. These results are consistent with the marked effects of ritonavir on a range of other cytochrome P450 substrates [27, 28] .
In vitro studies have indicated that sildena®l is not an inhibitor of CYP3A4 (IC 50 >300 mmol l x1 ) at clinically relevant concentrations (< 1 mmol l x1 after a 100 mg dose) [4] . Accordingly, sildena®l (100 mg) did not signi®cantly affect the steady-state pharmacokinetics of either saquinavir or ritonavir in this study. This suggests that the antiretroviral ef®cacy of these protease inhibitors is unlikely to be affected by coadministered sildena®l.
The signi®cant increase in systemic exposure to sildena®l, resulting from coadministration with the protease inhibitors (in particular ritonavir), was not associated with an increase in the incidence of adverse effects or laboratory abnormalities. The pattern of reported adverse events in this volunteer study was consistent with that noted in large-scale clinical trials of sildena®l, in which headache, facial¯ushing, dyspepsia and nasal congestion occur most frequently [29] . Given that it is C max which primarily in¯uences the frequency and severity of sildena®l adverse events and that sildena®l is well tolerated upto doses of 800 mg [4] it is not surprising that the adverse event pro®le even in the presence of ritonavir was not signi®cantly affected. The adverse effects of sildena®l, are described as dose-related over the range 50±200 mg, but are usually mild and transient in nature [2] . In view of this, consideration of a lower starting dose (25 mg) is an advisable precaution in patients concomitantly receiving protease inhibitors. Given the extent and duration of the effects of ritonavir, it is recommended not to exceed a maximum dose of 25 mg in a 48 h period.
In summary, saquinavir and ritonavir signi®cantly modi®ed the pharmacokinetics of sildena®l resulting in increased plasma concentrations of both drug and metabolite. The effect was considerably more pronounced with ritonavir than with saquinavir, although neither drug signi®cantly altered the safety or tolerability of sildena®l. Given the extent of the interactions, a lower sildena®l starting dose (25 mg) should be considered for patients receiving saquinavir whilst it is recommended not to exceed a maximum single dose of 25 mg in a 48 h period for patients receiving ritonavir. As sildena®l did not affect the steady-state pharmacokinetic pro®le of either saquinavir or ritonavir, the clinical effectiveness of protease inhibitor therapy is unlikely to be compromised by coadministration of sildena®l.
